We have been pioneers in the cocrystal field since 2006. Contact us to know their potential!
The big advantage of cocrystals compared to salts is that cocrystallisation is also applicable to non- ionisable molecules where salt formation is not possible. Compared to amorphous solid forms, cocrystals tend to be more stable and have a more
As a result of the increasing relevance of these solid forms, both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued guideline documents related to their regulatory classification.
We have been a pioneer in the cocrystal field, working in the area since 2006 and gaining significant expertise. Cocrystals offer great potential:
Over the last years, the number of pharmaceutical cocrystals has been increasing dramatically. Their novelty, utility and not obvious preparation make cocrystals an interesting approach from the point of view of intellectual property. In the case of commercial APIs, a patent of a cocrystal with better drug properties than previously known forms could be of high commercial value.
Cocrystals do not involve structural modification of the parent molecules, therefore, in the case of designing cocrystals of marketed drugs, their development programs (including clinical trials) will be significantly shorter and less risky than those of New Chemical Entities (NCEs).